Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

被引：0

作者：

Beypinar, Ismail ^{[1
]}

Demir, Hacer ^{[2
]}

Yaslikaya, Sendag ^{[3
]}

Koseci, Tolga ^{[3
]}

Demir, Bilgin ^{[4
]}

Colak, Gokhan ^{[4
]}

Agaoglu, Ahmet Burak ^{[5
]}

Sahbazlar, Mustafa ^{[5
]}

Sanci, Pervin Can ^{[6
]}

Cabuk, Devrim ^{[6
]}

Isik, Ulas ^{[7
]}

Sahin, Elif ^{[7
]}

Coskun, Alper ^{[8
]}

Caner, Burcu ^{[8
]}

Aykut, Talat ^{[9
]}

Artac, Mehmet ^{[9
]}

Duygulu, Mustafa Emre ^{[10
]}

Sever, Nadiye ^{[11
]}

Oksuz, Sila ^{[12
]}

Turan, Nedim ^{[12
]}

Aykan, Musa Baris ^{[13
]}

Tuzun, Esmanur Kaplan ^{[13
]}

Uysal, Mukremin ^{[14
]}

Ugurlu, Irem ^{[15
]}

Sakin, Abdullah ^{[16
]}

Acar, Caner ^{[17
]}

Ozaskin, Duygu ^{[2
]}

Sakalar, Teoman ^{[18
]}

Keskinkilic, Merve ^{[19
]}

Yavuzsen, Tugba ^{[19
]}

Kose, Naziyet ^{[20
]}

Erturk, Ismail ^{[13
]}

Yildirim, Nilgun ^{[21
]}

Balcik, Onur Yazdan ^{[1
]}

Alkan, Ali ^{[22
]}

Selvi, Oguzhan ^{[23
]}

Ercin, Eda ^{[24
]}

Unal, Olcun Umit ^{[25
]}

Karacin, Cengiz ^{[26
]}

机构：

[1] Alanya Alaaddin Keykubat Univ, Dept Med Oncol, Alanya, Turkiye

[2] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, Afyon, Turkiye

[3] Cukurova Univ, Dept Med Oncol, Adana, Turkiye

[4] Adnan Menderes Univ Hosp, Dept Med Oncol, Aydin, Turkiye

[5] Celal Bayar Univ, Dept Med Oncol, Manisa, Turkiye

[6] Kocaeli Univ, Dept Med Oncol, Kocaeli, Turkiye

[7] Kocaeli City Hosp, Dept Med Oncol, Kocaeli, Turkiye

[8] Uludag Univ, Dept Med Oncol, Bursa, Turkiye

[9] Necmettin Erbakan Univ, Dept Med Oncol, Konya, Turkiye

[10] Karadeniz Tech Univ, Dept Med Oncol, Trabzon, Turkiye

[11] Marmara Univ, Dept Med Oncol, Istanbul, Turkiye

[12] Kartal Lutfu Kirdar Res & Educ Hosp, Dept Med Oncol, Istanbul, Turkiye

[13] Gulhane Educ & Res Hosp, Dept Med Oncol, Ankara, Turkiye

[14] Antalya Bilim Univ, Medstar Antalya Hosp, Vocat Sch Hlth Serv, Dept Med Oncol, Antalya, Turkiye

[15] Sakarya Educ & Res Hosp, Dept Med Oncol, Sakarya, Turkiye

[16] Medipol Univ, Dept Med Oncol, Istanbul, Turkiye

[17] Ege Univ, Dept Med Oncol, Izmir, Turkiye

[18] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkiye

[19] Dokuz Eylul Univ, Dept Med Oncol, Izmir, Turkiye

[20] Mem Hosp, Dept Med Oncol, Ankara, Turkiye

[21] Firat Univ, Dept Med Oncol, Elazig, Turkiye

[22] Mugla Sitki Kocman Univ, Dept Med Oncol, Mugla, Turkiye

[23] Prof Dr Cemil Tascioglu City Hosp, Dept Med Oncol, Istanbul, Turkiye

[24] Umraniye Res & Educ Hosp, Dept Med Oncol, Istanbul, Turkiye

[25] Tepecik Res & Educ Hosp, Dept Med Oncol, Izmir, Turkiye

[26] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkiye

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2024年 / 208卷 / 03期

关键词：

Everolimus; Breast cancer; Cyclin-dependent Kinase Inhibitors; Palbociclib; Ribociclib; Life experience; METASTATIC BREAST-CANCER; EXEMESTANE; MULTICENTER; PALBOCICLIB; FULVESTRANT; RESISTANCE; THERAPY; SAFETY; MTOR;

D O I：

10.1007/s10549-024-07456-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.

引用

页码：597 / 604

页数：8

共 28 条

[1] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[2] Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study [J].

Bilici, Ahmet ;

Uysal, Mukremin ;

Menekse, Serkan ;

Akin, Semih ;

Yildiz, Fatih ;

Turan, Merve ;

Sezgin Goksu, Sema ;

Beypinar, Ismail ;

Sakalar, Teoman ;

Degirmenci, Mustafa ;

Erdem, Dilek ;

Basaran, Gul ;

Olmez, Omer Fatih ;

Avci, Nilufer ;

Tural, Deniz ;

Sakin, Abdullah ;

Turker, Sema ;

Demir, Atakan ;

Temiz, Suleyman ;

Kaplan, Muhammed Ali ;

Dogan, Mutlu ;

Tanriverdi, Ozgur ;

Bilgetekin, Irem ;

Cinkir, Havva Yesil ;

Acikgoz, Ozgur ;

Paydas, Semra ;

Uslu, Ruchan ;

Turhal, Serdar .

CANCER INVESTIGATION, 2022, 40 (02) :199-209

[3] Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer [J].

Boulay, A ;

Rudloff, J ;

Ye, JJ ;

Zumstein-Mecker, S ;

O'Reilly, T ;

Evans, DB ;

Chen, SU ;

Lane, HA .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5319-5328

[4] Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial [J].

Burris, Howard A., III ;

Lebrun, Fabienne ;

Rugo, Hope S. ;

Beck, J. Thaddeus ;

Piccart, Martine ;

Neven, Patrick ;

Baselga, Jose ;

Petrakova, Katarina ;

Hortobagyi, Gabriel N. ;

Komorowski, Anna ;

Chouinard, Edmond ;

Young, Robyn ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Bennett, Lee ;

Ricci, Jean-Francois ;

Bauly, Hounayda ;

Taran, Tetiana ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo .

CANCER, 2013, 119 (10) :1908-1915

[5] 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [J].

Cardoso, F. ;

Costa, A. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. ;

Biganzoli, L. ;

Cardoso, M. J. ;

Carey, L. ;

Corneliussen-James, D. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. ;

Eniu, A. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Gennari, A. ;

Harbeck, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Mayer, M. ;

Meijer, H. ;

Mertz, S. ;

Ohno, S. ;

Pagani, O. ;

Papadopoulos, E. ;

Peccatori, F. ;

Pernault-Llorca, F. ;

Piccart, M. J. ;

Pierga, J. Y. ;

Rugo, H. ;

Shockney, L. ;

Sledge, G. ;

Swain, S. ;

Thomssen, C. ;

Tutt, A. ;

Vorobiof, D. ;

Xu, B. ;

Norton, L. ;

Winer, E. .

BREAST, 2017, 31 :244-259

[6] Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR plus ) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study [J].

Cazzaniga, M. E. ;

Airoldi, M. ;

Arcangeli, V. ;

Artale, S. ;

Atzori, F. ;

Ballerio, A. ;

Bianchi, G. V. ;

Blasi, L. ;

Campidoglio, S. ;

Ciccarese, M. ;

Cursano, M. C. ;

Piezzo, M. ;

Fabi, A. ;

Ferrari, L. ;

Ferzi, A. ;

Ficorella, C. ;

Frassoldati, A. ;

Fumagalli, A. ;

Garrone, O. ;

Gebbia, V. ;

Generali, D. ;

La Verde, N. ;

Maur, M. ;

Michelotti, A. ;

Moretti, G. ;

Musolino, A. ;

Palumbo, R. ;

Pistelli, M. ;

Porpiglia, M. ;

Sartori, D. ;

Scavelli, C. ;

Schirone, A. ;

Turletti, A. ;

Valerio, M. R. ;

Vici, P. ;

Zambelli, A. ;

Clivio, L. ;

Torri, V. .

BREAST, 2017, 35 :115-121

[7] Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy [J].

Cook, Madeline M. ;

Al Rabadi, Luai ;

Kaempf, Andy J. ;

Saraceni, Megan M. ;

Savin, Michael A. ;

Mitri, Zahi I. .

ONCOLOGIST, 2021, 26 (02) :101-106

[8] Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3 [J].

Cristofanilli, Massimo ;

DeMichele, Angela ;

Giorgetti, Carla ;

Turner, Nicholas C. ;

Slamon, Dennis J. ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Verma, Shailendra ;

Loi, Sherene ;

Colleoni, Marco ;

Puyana Theall, Kathy ;

Huang, Xin ;

Liu, Yuan ;

Huang Bartlett, Cynthia .

EUROPEAN JOURNAL OF CANCER, 2018, 104 :21-31

[9] Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib [J].

Dhakal, Ajay ;

Thomas, Roby Antony ;

Levine, Ellis G. ;

Brufsky, Adam ;

Takabe, Kazuaki ;

Hanna, Matthew G. ;

Attwood, Kristopher ;

Miller, Austin ;

Khoury, Thaer ;

Early, Amy P. ;

Soniwala, Saif ;

O'Connor, Tracy ;

Opyrchal, Mateusz .

BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14

[10] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

← 1 2 3 →